Trials / Completed
CompletedNCT00206180
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | esomeprazole magnesium (oral medication) |
Timeline
- Start date
- 2004-06-01
- Completion
- 2005-08-01
- First posted
- 2005-09-21
- Last updated
- 2009-03-26
Locations
39 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00206180. Inclusion in this directory is not an endorsement.